Exocobio Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jul 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Cosmetic composition comprising rose stem cell-derived exosome as effective ingredient (US 11,690,797) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Composition for alleviating facial redness, comprising stem cell-derived exosomes as active ingredient (US 11,730,695) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Composition comprising sapogenin and exosome as effective ingredient (US 11,850,297) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,446,333 | Use of composition comprising stem cell-derived exosome as effective ingredient for suppression or alleviation of pruritus In force · From the USPTO record | In force | From the USPTO record | |
| US 11,337,419 | Method for lyophilizing exosome In force · From the USPTO record | In force | From the USPTO record | |
| US 11,730,695 | Composition for alleviating facial redness, comprising stem cell-derived exosomes as active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,529,370 | Use of composition comprising stem cell-derived exosome as effective ingredient in strengthening skin barrier and improving skin barrier function In force · From the USPTO record | In force | From the USPTO record | |
| US 11,534,392 | Cosmetic composition comprising exosomes derived from galactomyces as active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,612,621 | Use of composition comprising exosome derived from adipose-derived stem cell as effective ingredient in ameliorating dermatitis In force · From the USPTO record | In force | From the USPTO record | |
| US 11,690,797 | Cosmetic composition comprising rose stem cell-derived exosome as effective ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,529,306 | Lyophilized formulation of stem cell-derived exosomes and anti-inflammatory composition including the same as active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,850,297 | Composition comprising sapogenin and exosome as effective ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 12,636,337 | Composition for Anti-Inflammation, Wound Healing or Wound Healing Promotion, Comprising Rose Stem Cell-Derived Exosomes as Active Ingredient In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 3 no status recorded